RNS2 Dec 2021 11:31
The RNS explicitly refers to Venafi's investment as being 'strategic'. According to the FCA, this has a specific meaning:
"strategic investment
an investment which:
(a) is made for a strategic purpose;
(b) is made for an expected duration consistent with that purpose and is, or has the potential to be, illiquid or hard to value; and
(c) is significant in value in proportion to the size of the with-profits fund.
"
(https://www.handbook.fca.org.uk/handbook/glossary/G2925.html)
So the question is, what is Venafi's strategy? Given that they already use Keyscaler. And what are the possible implications of this? Venafi are not fools. They've seen an opportunity. If, as the FCA definition suggests, the investment is for an expected duration, what event is expected at the end of that duration?
Furthermore, the share structure of DA has now ben greatly simplified. Instead of Tern being due 42% or thereabouts of the sale revenue plus a few add-on, we now get a set 53.8% of the sale revenue, whatever that may eventually be.
None of this is what I'd hoped for, although even then I was expecting this kind of development in the new year. But in my opinion, this sums to being a sign of positive things to come. I don't think this lessens the potential for a high value sale in 2022, hopefully in Q1. Just my opinion only.